Skip to main content
Premium Trial:

Request an Annual Quote

Cepheid s Revenues, Losses Climb in Q4

NEW YORK, Feb. 18 (GenomeWeb News) - Cepheid reported higher revenues as well as losses for the fourth quarter of 2003 yesterday.


The company's revenues for the quarter totaled $5.3 million, up from $4.7 million during the same period last year.


R&D expenses increased slightly, to $4 million, from $3.8 million in the fourth quarter of 2002.


Cepheid's net loss climbed to $4.5 million, or $.13 per share, from $3.5 million, or $.11 per share, during the year-ago period.


As of Dec. 31, the company had cash and cash equivalents of $18.5 million.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.